Tiziana Life Sciences plc TLSA 深 沪
已收盘 02-06 16:00:00 美东时间
1.36
+0.090
+7.09%
华盛通- 最 高1.39
- 今 开1.28
- 成交量 23.01万股
- 最 低 1.27
- 昨 收 1.27
- 总市值 1.73亿
- 52周最高 2.60
- 市盈率 静 --
- 换手率 0.18%
- 52周最低 0.7301
- 委 比 80.85%
- 总股本 1.27亿
- 历史最高 12.15
- 量 比 1.01
- 振 幅 9.45%
- 历史最低 0.41
- 每 手 1
- 风险率 0.37%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Tiziana Life Sciences Prices $8M Registered Direct Offering To Management And Shareholders, Issues Warrants For Potential $9.6M Upside
Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana"), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the pricing of a Company best
01-16 20:03
Tiziana Life Sciences Announces Closing of Oversubscribed $8.8 Million Registered Direct Offering of Ordinary Shares
Tiziana Life Sciences announced the closing of a registered direct offering of 7,040,000 ordinary shares at $1.25 per share, raising $8.8 million in gross proceeds. Participants also received warrants to purchase additional shares at $1.50, potentially adding up to $10.56 million. The company's CEO, Ivor Elrifi, and Executive Chairman, Gabriele Cerrone, participated significantly. Proceeds will support Phase 2 clinical trials for their lead candi...
01-16 19:45
Tiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San Francisco
Tiziana Life Sciences Ltd. announced that CEO Ivor Elrifi will present at the 9th Annual Neuroscience Innovation Forum on January 11, 2026, in San Francisco. The presentation will highlight Tiziana's lead candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody designed to modulate the immune system and reduce neuroinflammation. The forum, organized by Sachs Associates, will also allow Tiziana's senior management to meet with i...
01-09 12:00
Tiziana Life Sciences Submits Seventh Annual Development Safety Update Report For Foralumab To FDA
Tiziana reports excellent safety profile with intranasal foralumab after 37.4 patient-years cumulative exposure
2025-12-29 21:04
Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA
Tiziana Life Sciences reported the submission of its seventh annual Development Safety Update Report (DSUR) to the FDA, highlighting the excellent safety profile of intranasal foralumab with no drug-related serious adverse events after 37.4 patient-years of cumulative exposure. The FDA's denial of Sanofi’s tolebrutinib for nrSPMS emphasizes the need for safe therapies in neuroinflammatory disorders. Tiziana's intranasal foralumab demonstrates sig...
2025-12-29 13:00
Tiziana Life Sciences withdraws proposed public offering
Tiziana Life Sciences (TLSA) announced on Monday the withdrawal of the proposed public offering of common shares due to market conditions. Tiziana Life Sciences (TLSA) shares were up 4% in premarket ...
2025-12-15 21:15
Tiziana Life Sciences Begins Enrollment In Phase 2 Alzheimer's Trial Of Intranasal Foralumab, Plans First Dosing Next Week As New PET Data Shows Persistent Neuroinflammation Despite Leqembi Treatment
First Patient Expected to be Dosed Next Week with Intranasal ForalumabPET Scan Shows Presence of Untreated Neuroinflammation in Alzheimer's Patient on Leqembi® (Lecanemab) Anti-Amyloid TherapyBOSTON, Dec. 12,
2025-12-13 03:12
Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer’s Trial
Tiziana Life Sciences announces the start of a Phase 2 clinical trial for intranasal foralumab in early Alzheimer's disease (AD). The trial will evaluate the therapy both as monotherapy and in combination with FDA-approved anti-amyloid therapies, lecanemab or donanemab. Baseline assessments, including TSPO-PET imaging, have shown persistent neuroinflammation in AD patients despite amyloid plaque reduction, suggesting a need to target residual inf...
2025-12-12 19:10
Tiziana Life Sciences' Phase 2 Clinical Trial Evaluating Intranasal Foralumab In ALS Patients Accepted For Inclusion In ALS MyMatch Program
Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies, today announced that its Phase 2 clinical trial evaluating intranasal
2025-11-25 21:33
Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference
Tiziana Life Sciences announced that its senior leadership team will present at the Jefferies London Healthcare Conference on November 19, 2025. The presentation will focus on the Company’s innovative pipeline, particularly its lead candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody for neurodegenerative diseases. Foralumab has shown promise in treating conditions like non-active secondary progressive multiple sclerosis (...
2025-11-13 13:30
